Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the ...

Meanwhile, the FDA has asked manufacturers of flu vaccines to update their labels to include warnings about the risk of ...

Hippocratic AI has expanded its focus with the acquisition of Grove AI, a specialist in AI used in pharma R&D, to complement ...

Illumina has unveiled a database of genomic alterations, called the Billion Cell Atlas, that can be used to identify and ...

For the US, it means that the UK will spend more on medicines and offer more support to industry. Over the next ten years, ...

In this exclusive video interview, pharmaphorum’s editor-in-chief Jonah Comstock sits down with Carlos Buesa, CEO of Oryzon ...

Former Moderna executive Dr Melanie Ivarsson has been appointed chief executive of the UK's Health Data Research Service ...

In our final batch of Changing Faces columns for 2025, we’re detailing a flurry of senior leadership appointments in recent ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...

Anthropic has launched Claude for Healthcare, a suite of AI tools for health systems, payers, and patients, in the latest ...

AbbVie has joined many of its big pharma peers by signing a Most-Favoured Nation (MFN) drug pricing deal with the Trump ...

The US regulator has approved Sentynl Therapeutics Zycubo (copper histidinate; formerly known as CUTX-101) as a treatment for ...